Polyplus-transfection Enters Reagent Deal with Roche Glycart

Jan 24, 2011

NEW YORK (GenomeWeb News) – Polyplus-transfection announced today it has granted a non-exclusive license to Roche Glycart for use of polyethylenimine for in vitro transfection applications for research purposes.

As a result, Roche Glycart will be able to use the transfection reagent to produce antibody-based products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Capturing Diversity

A company hopes to capture the genetic diversity in India to power tailored therapeutics, BBC News reports.

Sleepless Genes

Researchers tie variants in seven genes to insomnia risk, Live Science reports.

RNAi Insecticide Within Corn

The US Environmental Protection Agency has approved an RNAi-based insecticide, according to the Atlantic.

This Week in PLOS

In PLOS this week: locus near OAS1 linked to Sjogren's syndrome, rotavirus reassortment events uncovered by sequencing, and more.

Main menu